Ovarian Cancer Risk Screening: A Review of Our Comprehensive £249 Package
Ovarian cancer risk screening is a structured group of blood tests that measure specific biomarkers — including CA-125 and HE4 — to provide an educational view of ovarian health. Our comprehensive £24
Ovarian cancer risk screening is a structured group of blood tests that measure specific biomarkers — including CA-125 and HE4 — to provide an educational view of ovarian health. Our comprehensive £249 package combines these markers with broader hormonal and metabolic context to support proactive monitoring as part of preventive women’s wellbeing.
Ovarian conditions are sometimes called "quiet" because early changes can be subtle. While no blood test can diagnose ovarian cancer on its own, modern biomarker panels can offer valuable contextual data that women and their healthcare professionals may use to inform follow-up decisions. This article explains what’s included in our £249 package, how the markers work together, and how to interpret results within an informational, screening-focused framework.
What Is Included in the £249 Comprehensive Package?
This package is designed to give women a broader, multi-marker view of ovarian and hormonal health, rather than relying on a single test in isolation. It is positioned as a screening and reporting service — not a diagnostic procedure.
The £249 ovarian cancer risk screening package may include:
- CA-125 — a glycoprotein associated with ovarian tissue activity
- HE4 (Human Epididymis Protein 4) — a complementary marker often used alongside CA-125
- ROMA index calculation — combining CA-125 and HE4 with menopausal status
- Female hormone context (where included) — supporting interpretation
- Detailed written report from a qualified nurse
Practical Insight: Multi-marker panels often provide richer context than single-marker tests, because each biomarker reflects a slightly different aspect of ovarian biology.
Understanding the Key Biomarkers
CA-125
CA-125 is a long-established biomarker used in ovarian health monitoring. Levels can be influenced by ovarian conditions but also by menstruation, endometriosis, fibroids, pregnancy, and certain non-ovarian conditions. This is why CA-125 is interpreted in context rather than in isolation.
HE4
HE4 is considered to have improved specificity in premenopausal women, where CA-125 alone can be affected by benign gynaecological factors. Combining HE4 with CA-125 may reduce some of these contextual influences.
For a deeper look at why HE4 is often paired with CA-125, see our article on why HE4 may offer improved specificity compared to CA-125 in premenopausal women.
ROMA Index
The ROMA (Risk of Ovarian Malignancy Algorithm) index combines CA-125, HE4, and menopausal status to produce a risk-grouping score. It is an educational interpretation aid — not a diagnostic conclusion.
How This Package Compares to Standard Single-Marker Testing
| Feature | Standard CA-125 Only | £249 Comprehensive Ovarian Risk Package |
|---|---|---|
| Markers included | CA-125 | CA-125 + HE4 (+ ROMA where applicable) |
| Specificity in premenopausal women | Limited (affected by menstruation, fibroids, endometriosis) | Improved with HE4 + ROMA context |
| Interpretation depth | Single-value result | Multi-marker pattern review |
| Written nurse-led report | Often not included | Included |
| Best suited to | Basic single-marker check | Women seeking a broader, contextual screening view |
Practical Insight: A multi-marker approach can give clearer context, especially for premenopausal women, where single-marker results are more easily influenced by benign factors.
Who Should Consider Ovarian Cancer Risk Screening?
This screening is educational and proactive, not diagnostic. It may be relevant for women who:
- Want a structured baseline for ovarian and hormonal markers
- Have a family history of ovarian or related conditions
- Have noticed persistent, non-specific abdominal or pelvic changes
- Are interested in proactive long-term monitoring
- Have previously had borderline CA-125 results
For wider context, our guide on silent symptoms — why ovarian cancer is often called a quiet disease explains why subtle, persistent changes may justify a closer look. If symptoms are severe, urgent medical care should be sought.
How Often Should You Test?
Frequency should be individualised, but common educational guidance includes:
- Baseline screening: once, to establish your starting reference point
- Routine review: typically every 12 months for ongoing monitoring
- After borderline results: earlier follow-up as advised by a qualified healthcare professional
- Family history considerations: review intervals may be discussed with your healthcare professional
Trends over time are often more meaningful than a single result, because biomarkers can fluctuate naturally.
What Do the Results Mean?
Results are best interpreted as patterns, not isolated numbers. A nurse-led report may highlight:
- Whether CA-125 and HE4 are within typical reference ranges
- How values compare with menopausal status (via ROMA where applicable)
- Whether retesting in a defined window may be useful
- How current results compare with any previous tests
A result outside the reference range does not, on its own, confirm any condition. It is a signal worth discussing with a qualified healthcare professional, who can review symptoms, history, and any further investigations indicated.
For broader interpretation guidance, see our resource on when abnormal results should trigger further tests.
London and UK Context
In London and across the UK, women are increasingly choosing private ovarian health screening for convenience, faster turnaround, and broader marker coverage. NHS pathways focus on clinically indicated investigations, while private screening allows for proactive, educational review. Both routes are valid and complementary — the right choice depends on your goals.
You can review broader options through our women’s health screening packages page.
Why Local Relevance Matters for London Women
London’s pace of life, demanding schedules, and pressures around accessing structured women’s health screening lead many women to seek private, nurse-led options. A multi-marker ovarian screening package provides a quiet, structured way to review key biomarkers without disruption to busy routines.
Frequently Asked Questions
What does the £249 ovarian cancer risk screening package include?
It includes CA-125, HE4, and (where applicable) the ROMA index calculation, alongside a detailed nurse-led written report. It is designed to give women a broader, contextual view of ovarian health markers as part of proactive screening, rather than as a diagnostic test.
Is ovarian cancer risk screening a diagnostic test?
No. Ovarian cancer risk screening is an educational and informational tool. Biomarkers can highlight patterns that may be relevant to ovarian health, but they cannot diagnose any condition. Results should always be reviewed with a qualified healthcare professional in the appropriate clinical context.
Why are CA-125 and HE4 measured together?
CA-125 alone can be influenced by benign factors such as menstruation, fibroids, and endometriosis, particularly in premenopausal women. HE4 may offer improved specificity in this group, so combining the two markers — often with ROMA — provides a richer contextual view than a single test.
Do I need to fast before the test?
Fasting is not usually required for CA-125 or HE4. However, if additional metabolic or hormonal markers are added to your screening, fasting may be requested. Specific instructions are provided when booking your ovarian cancer risk screening appointment.
Can my results be normal but I still have symptoms?
Yes. No screening test is 100% sensitive. Normal results provide reassurance within the context of the markers tested, but persistent or worsening symptoms should always be discussed with a qualified healthcare professional, who can advise on appropriate next steps.
How often should I take the £249 ovarian cancer risk screening package?
A common approach is annual review for ongoing monitoring, with earlier follow-up if a previous result was borderline or if symptoms change. Frequency should be individualised based on personal history and clinical advice.
Is private screening worth it compared to NHS pathways?
Private screening can offer convenience, broader marker coverage, and faster turnaround. NHS investigations remain available for clinically indicated cases. Many women use private screening for proactive monitoring, while continuing to access NHS pathways for ongoing care.
What happens if my results are outside the reference range?
A result outside the reference range is not a diagnosis. It is a signal worth reviewing with a qualified healthcare professional, who can interpret it within the wider context of symptoms, history, and any further investigations that may be indicated.
Taking the Next Step
Proactive wellbeing starts with knowledge. If you are considering a structured way to review your ovarian and hormonal markers, the £249 comprehensive ovarian cancer risk screening package can be a useful starting point as part of broader preventive health planning.
You can review our wider screening packages for further educational resources.